866775-17-9

Usage

Uses

Used in Pharmaceutical Industry:
3-Amino-5-trifluoromethyl-pyridine-2-carboxylic acid methyl ester is used as a building block for the synthesis of various biologically active compounds, including pharmaceuticals. Its unique structure with a trifluoromethyl group and an amino group in the pyridine ring allows for the development of new drugs with improved potency and selectivity.
Used in Agrochemical Industry:
3-Amino-5-trifluoromethyl-pyridine-2-carboxylic acid methyl ester is used as a building block for the synthesis of agrochemicals, such as insecticides and herbicides. Its chemical properties make it suitable for the development of new compounds with enhanced efficacy and selectivity in controlling pests and weeds.
Used in Organic Synthesis:
3-Amino-5-trifluoromethyl-pyridine-2-carboxylic acid methyl ester is used as a reagent in organic synthesis. Its versatile structure allows for the synthesis of a wide range of compounds, making it a valuable tool for chemists in various research and industrial applications.

Upstream product

• 655235-65-7 methyl 3-chloro-5-(trifluoromethyl)pyridine-2-carboxylate 
• 67-56-1 methanol 
• 866775-16-8 3-nitro-5-trifluoromethyl-pyridine-2-carbonitrile 
• 1211515-30-8 3-amino-5-(trifluoromethyl)picolinonitrile 
• 1214336-90-9 3-amino-6-(2,6-difluorophenyl)-5-trifluoromethyl-2-pyridinecarboxylicacid 
• 33252-64-1 3-nitro-5-trifluoromethylpyridin-2-ol 
• 72587-15-6 2-chloro-3-nitro-5-(trifluoromethyl)pyridine 

Downstream Products

• 866775-18-0 3-amino-6-bromo-5-trifluoromethyl-pyridine-2-carboxylic acid methyl ester 
• 1334546-83-6 3-amino-6-(2,4-dichlorophenyl)-5-trifluoromethylpyridine-2-carboxylic acid 
• 1214370-77-0 3-amino-5-trifluoromethylpyridine-2-carboxylic acid 
• 1334547-21-5 3-amino-6-(4-fluorophenyl)-5-trifluoromethylpyridine-2-carboxylic acid 
• 1334547-23-7 3-amino-6-(2,4-dichlorophenyl)-5-trifluoromethylpyridine-2-carboxylic acid methyl ester 
• 1334546-80-3 3-amino-6-(4-fluorophenyl)-5-trifluoromethylpyridine-2-carboxylic acid ((S)-3,3,3-trifluoro-2-hydroxy-2-methylpropyl)amide 
• 1427262-61-0 3-amino-6-bromo-N'-(2-phenylacetyl)-5-(trifluoromethyl)picolinohydrazide 
• 1427262-60-9 2-(5-benzyl-1,3,4-oxadiazol-2-yl)-6-bromo-5-(trifluoromethyl)pyridin-3-amine 
• 1427262-81-4 (R)-benzyl 2-(2-(3-amino-6-bromo-5-(trifluoromethyl)picolinoyl)hydrazinyl)-2-oxo-1-phenylethylcarbamate 
• 1427262-83-6 (R)-benzyl (5-(3-amino-6-bromo-5-(trifluoromethyl)pyridin-2-yl)-1,3,4-oxadiazol-2-yl)(phenyl)methylcarbamate 
• 1427262-80-3 (R)-2-(5-(amino(phenyl)methyl)-1,3,4-oxadiazol-2-yl)-6-bromo-5-(trifluoromethyl)pyridin-3-amine 
• 1427400-35-8 methyl 3-amino-6-(4-fluorophenyl)-5-(trifluoromethyl)picolinate 
• 1427400-25-6 3-amino-6-(4-fluorophenyl)-N-(1H-pyrazol-3-yl)-5-(trifluoromethyl)picolinamide 

Relevant academic research and scientific papers

MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR

This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR), pharmaceutical compositions containing at least one such modulator, methods of treatment of cystic fibrosis using such modulators and pharmaceutical compositions, and processes for making such modulators.

Discovery of Icenticaftor (QBW251), a Cystic Fibrosis Transmembrane Conductance Regulator Potentiator with Clinical Efficacy in Cystic Fibrosis and Chronic Obstructive Pulmonary Disease

Mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) ion channel are established as the primary causative factor in the devastating lung disease cystic fibrosis (CF). More recently, cigarette smoke exposure has been shown to be asso

Pyridine and Pyrazine derivative for the Treatment of CF, COPD, and Bronchiectasis

The present invention provides pyridine and pyrazine derivatives which restore or enhance the function of mutant and/or wild type CFTR to treat bronchiectasis, cystic fibrosis, primary ciliary dyskinesia, chronic bronchitis, chronic obstructive pulmonary disease, asthma, respiratory tract infections, lung carcinoma, xerostomia and keratoconjunctivitis sire, or constipation (IBS, IBD, opioid induced). Pharmaceutical compositions comprising such derivatives are also encompassed.

HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF CYSTIC FIBROSIS

The present invention provides pyridin-oxadiazole/thiadiazole derivatives of Formula I wherein A is N or CR 4a; and (ii) or (iii) which restore or enhance the function of mutant and/or wild type CFTR to treat cystic fibrosis, primary ciliary dyskinesia, chronic bronchitis, chronic obstructive pulmonary disease, asthma, respiratory tract infections, lung carcinoma, xerostomia and keratoconjunctivitis sire, or constipation (IBS, IBD, opioid induced). Pharmaceutical compositions comprising such derivatives are also encompassed.

PYRIDINE AMIDE DERIVATIVES

The present invention provides pyridine derivatives which restore or enhance the function of mutant and/or wild type CFTR to treat cystic fibrosis, primary ciliary dyskinesia, chronic bronchitis, chronic obstructive pulmonary disease, asthma, respiratory

Pyridine amide derivatives

The present invention provides pyridine amide derivatives which re? store or enhance the function of mutant and/or wild type CFTR to treat cystic fibrosis, primary ciliary dyskinesia, chronic bronchitis, chronic obstructive pulmonary disease, asthma, resp

PYRIDINE/PYRAZINE AMIDE DERIVATIVES

The present invention provides pyridine/pyrazine amide derivatives which restore or enhance the function of mutant and/or wild type CFTR to treat cystic fibrosis, primary ciliary dyskinesia, chronic bronchitis, chronic obstructive pulmonary disease, asthm

N-SUBSTITUTED HETEROCYCLYL CARBOXAMIDES

A compound of Formula I and pharmaceutically acceptable salts and solvates thereof, wherein R1, R2, R3, Ra, A, B, D and E are all as defined herein. The compounds modulate the activity of CFTR and are useful in

Pyridine and Pyrazine derivative for the Treatment of CF

The present invention provides pyridine and pyrazine derivatives which restore or enhance the function of mutant and/or wild type CFTR to treat cystic fibrosis, primary ciliary dyskinesia, chronic bronchitis, chronic obstructive pulmonary disease, asthma, respiratory tract infections, lung carcinoma, xerostomia and keratoconjunctivitis sire, or constipation (IBS, IBD, opioid induced). Pharmaceutical compositions comprising such derivatives are also encompassed.

COMPOUNDS AND METHODS FOR TREATING DYSLIPIDEMIA

The present invention discloses compounds of formula I wherein A, n, m, j, q, K, W, X, K, Z, R1, R2, R3, R4, R5, and R6 are as defined herein and their pharmaceutical compositions and methods of use are disclosed as useful for treating dyslipidemia and its sequelae.